Michael Marino compensation by year
OptiNose Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $431,628 | $453,209 |
| Bonus | $0 | $100,000 |
| Stock awards | $104,951 | $293,313 |
| Option awards | $287,506 | $242,840 |
| Non-equity incentive | $157,328 | $216,181 |
| Pension and deferred compensation | $0 | $0 |
| All other | $15,281 | $16,557 |
| Total | $996,694 | $1,322,100 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OptiNose, Inc. DEF 14A filed April 26, 2024, accession 0001494650-24-000047, and prior-year filings. Open the filing on EDGAR.
How this page was built: the OptiNose, Inc. filed document, accession 0001494650-24-000047. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 208,950 | $269,546 | — |
| Option | 110,790 | — | $1.85 |
| Option | 44,320 | — | $1.85 |
| Option | 25,000 | — | $3.51 |
| Option | 2,866 | — | $5.41 |
| Option | 185,250 | — | $1.90 |
Per the Outstanding Equity Awards at Fiscal Year-End table in OptiNose, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
14 Form 4 lines since the FY2023 proxy (filed April 26, 2024)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-05-21 | Disposition to the issuer derivative | — | 3,056 | — | 0 |
| 2025-05-21 | Disposition to the issuer derivative | — | 5,775 | — | 0 |
| 2025-05-21 | Disposition to the issuer derivative | — | 9,626 | — | 0 |
| 2025-05-21 | Disposition to the issuer derivative | — | 16,752 | — | 0 |
| 2025-05-21 | Disposition to the issuer derivative | — | 5,500 | — | 0 |
| 2025-05-21 | Disposition to the issuer derivative | — | 5,333 | — | 0 |
| 2025-05-21 | Disposition to the issuer | — | 125,204 | — | 0 |
| 2025-05-21 | Disposition to the issuer derivative | — | 10,575 | — | 0 |
The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
OptiNose’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Ramy Mahmoud | Chief Executive Officer and Director | $2,414,265 |
| Peter Miller | Former Chief Executive Officer | $1,694,471 |
| Michael Marino · this page | Chief Legal Officer and Corporate Secretary | $1,322,100 |
| Paul Spence | Chief Commercial Officer | $664,019 |
Michael Marino's compensation dossier, OptiNose
You have read Michael Marino's totals and holdings. The dossier adds each equity grant OptiNose disclosed for Michael Marino and OptiNose's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full OptiNose compensation record
free company briefThis page is one person within OptiNose's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OptiNose's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.